An observational study of synchronous/metachronous tumours in microsatellite unstable/mismatch repair deficient endometrial carcinomas

Objective: Microsatellite instability (MSI) is one of the genetic abnor-malities underlying endometrial carcinoma, especially endometrioid endometrial carcinoma (EEC). Microsatellite unstable endome-trial carcinomas may be associated with multiple primary malignancies. We aimed to document the incidence and type of associated tumours in MSI/mismatch repair deficient (MMR-d) endometrial car-cinomas at a single institution in South Africa. Methods: The study assessed EECs for the period 2009–2015 at a Johannesburg hospi-tal and followed on previous research undertaken in our department in which 66/145 MSI/MMR-d EECs were identified using immuno-histochemistry and polymerase chain reaction (PCR). After ethical clearance was granted, using the microsatellite unstable/MMR-d endometrial carcinoma case-specific laboratory reference numbers, a retrospective search and cross-reference for associated histologically proven tumours, was performed. Results: Three patients (4.5%) out of 66 confirmed MSI/MMR-d endometrial carcinoma cases had associated tumours, including an invasive squamous cell carcinoma of the cervix and mucinous breast carcinoma. One patient had two tu-mours, namely uterine leiomyosarcoma and rectal adenocarcinoma. The incidence of EEC patients with an associated tumour is signifi-cantly lower (p = 0.0045) than that documented in the United States of America (USA). Conclusion: Our study's incidence of associated tumours in MSI/MMR-d endometrial carcinoma patients was significantly lower than studies from the USA. The associated tumours in our study included traditional Lynch syndrome tumours such as colonic adenocarcinoma and demonstrated less commonly associated tumours, namely cervical carcinoma and uterine leiomyosarcoma. These findings highlight the need for further research in our population to assess risk factors and the true incidence of Lynch syndrome-associated tumours.

Lynch syndrome; Microsatellite instability; Endometrial carcinoma; South Africa; Metachronous tumours; Synchronous tumours

[1] GLOBOCAN 2020: New Global Cancer Data. Union for International Cancer Control. 2020. Available at: https://www.uicc .org/news/globocan-2020-new-global-cancer-data (Accessed: 7 February 2021).

[2] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[3] Sub-Saharan Africa. The Cancer Atlas. 2018. Available at: http: //canceratlas.cancer.org/n6X (Accessed: 7 February 2021).

[4] Global Cancer Observatory. 2020. Available at: https://gco.iarc.f r/ (Accessed: 24 June 2020).

[5] South African National Cancer Registry. National Cancer Registry: Cancer in South Africa 2017. 2017. Available at: https://www.nicd.ac.za/wp-content/uploads/2020/12/NCR_ 2017_Final_02dec2020.pdf (Accessed: 5 April 2021).

[6] Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open. 2017; 2: e000172.

[7] Karthikeyan VS, Sistla SC, Srinivasan R, Basu D, Panicker LC, Ali SM, et al. Metachronous Multiple Primary Malignant Neoplasms of the Stomach and the Breast: Report of Two Cases with Review of Literature. International Surgery. 2014; 99: 52–55.

[8] Uccella S, Cha SS, Melton LJ, Bergstralh EJ, Boardman LA, Keeney GL, et al. Risk factors for developing multiple malignancies in patients with endometrial cancer. International Journal of Gynecological Cancer. 2011; 21: 896–901.

[9] Rong C, Shi Y, Liang J. Multiple primary malignant neoplasms with endometrial carcinoma: a clinicopathological study of cases. International Journal of Clinical and Experimental Medicine. 2019; 12: 1747–1754.

[10] Lv M, Zhang X, Shen Y, Wang F, Yang J, Wang B, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine. 2017; 96: e6799.

[11] Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497: 67–73.

[12] Wadee R, Grayson W. A potpourri of pathogenetic pathways in endometrial carcinoma with a focus on Lynch Syndrome. Annals of Diagnostic Pathology. 2019; 39: 92–104.

[13] Bell DW, Ellenson LH. Molecular Genetics of Endometrial Carcinoma. Annual Review of Pathology: Mechanisms of Disease. 2019; 14: 339–367.

[14] Kim KR, Lax SF, Lazar AJ, Longacre TA, Malpica A, Matias-Guiu X, et al. Chapter 6, Tumours of the Uterine Corpus (pp. 246¬247). WHO Classification of tumour: Female genital tumours. 5th edn. Lyon (France): International Agency for Research on Cancer. 2020.

[15] Wadee R, Grayson W. Identification of possible Lynch syndrome in endometrial carcinomas at a public hospital in South Africa. Southern African Journal of Gynaecological Oncology. 2020; 12: 6–12.

[16] Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis. 2008; 29: 673–680.

[17] Wolf AI, Buchanan AH, Farkas LM. Historical review of Lynch syndrome. Journal of Coloproctology. 2013; 33: 095–110.

[18] Aarnio M. Clinicopathological Features and Management of Cancers in Lynch Syndrome. Pathology Research International. 2012; 2012: 350309.

[19] Wong A, Ngeow J. Hereditary Syndromes Manifesting as Endometrial Carcinoma: how can Pathological Features Aid Risk Assessment? BioMed Research International. 2015; 2015: 219012.

[20] Wadee R, Grayson W. Immunohistochemical mismatch repair deficiency versus PCR microsatellite instability: a tale of two methodologies in endometrial carcinomas. European Journal of Gynaecological Oncology. 2020; 41: 952–959.

[21] Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clinical Cancer Research. 2004; 10: 481–490.

[22] McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecologic Oncology. 2015; 137: 306–310.

[23] Vergouwe F, Boutall A, Stupart D, Algar U, Govender D, van der Linde GD, et al. Mismatch repair deficiency in colorectal cancer patients in a low-incidence area. South African Journal of Surgery. Suid-Afrikaanse Tydskrif Vir Chirurgie. 2013; 51: 16–21.

[24] Mills AM, Liou S, Ford JM, Berek JS, Pai RK, Longacre TA. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. American Journal of Surgical Pathology. 2014; 38: 1501–1509.

[25] Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of Lynch syndrome. Journal of Pathology. 2020; 250: 518–531.

[26] Stoll J, Rosenthal E, Cummings S, Willmott J, Bernhisel R, Kupfer SS. No Evidence of Increased Risk of Breast Cancer in Women with Lynch Syndrome Identified by Multigene Panel Testing. JCO Precision Oncology. 2020; 48: 51–60.

[27] Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. Journal of Clinical Oncology. 2012; 30: 958–964.

[28] de Angelis de Carvalho N, Niitsuma BN, Kozak VN, Costa FD, de Macedo MP, Kupper BEC, et al. Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 Germline Pathogenic Variants. Cancers. 2020; 12: 1848.

[29] Bansidhar BJ. Extracolonic manifestations of lynch syndrome. Clinics in Colon and Rectal Surgery. 2013; 25: 103–110.

[30] Antill YC, Dowty JG, Win AK, Thompson T, Walsh MD, Cummings MC, et al. Lynch syndrome and cervical cancer. International Journal of Cancer. 2015; 137: 2757–2761.

[31] Amer MH. Multiple neoplasms, single primaries, and patient survival. Cancer Management and Research. 2014; 6: 119–134.

[32] Barrow E, Hill J, Evans DG. Cancer risk in Lynch Syndrome. Familial Cancer. 2013; 12: 229–240.

[33] Clegg-Lamptey JNA, Amenuveve C, Hodasi WM. Hereditary Non-polyposis Colorectal Carcinoma (HNPCC) in a Ghanian family. East African Medical Journal. 2011; 88: 285–288.

[34] Katsidzira L, Vorster A, Gangaidzo IT, Makunike-Mutasa R, Govender D, Rusakaniko S, et al. Investigation on the hereditary basis of colorectal cancers in an African population with frequent early onset cases. PLoS ONE. 2019; 14: e0224023.

[35] Mehdi I, Shah AH, Moona MS, Verma K, Abussa A, Elramih R, et al. Synchronous and metachronous malignant tumours expect the unexpected. Journal of the Pakistan Medical Association. 2010; 60: 905–909.

[36] Mugala D, Musowoya J, Nkhata,G. Multiple Primary Malignancies in Patients: Case Reports of Five Patients in Northern Zambia. Medical Journal of Zambia. 2015; 42: 78–83.

[37] AIDSinfo UNAIDS. 2020. Available at: https://aidsinfo.unaids.or g/ (Accessed: 21 February 2021).

[38] Wistuba II, Behrens C, Milchgrub S, Virmani AK, Jagirdar J, Thomas B, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. Journal of the American Medical Association. 1998; 279: 1554–1559.

[39] Chambuso R, Kaambo E, Denny L, Gray CM, Williamson A, Migdalska-Sęk M, et al. Investigation of Cervical Tumor Biopsies for Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-1/HPV Coinfected Women. Frontiers in Oncology. 2019; 9: 951.